Dimensional Fund Advisors LP Invests $371,000 in Acelyrin, Inc. (NASDAQ:SLRN)

Dimensional Fund Advisors LP bought a new stake in Acelyrin, Inc. (NASDAQ:SLRN - Free Report) in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm bought 118,241 shares of the company's stock, valued at approximately $371,000. Dimensional Fund Advisors LP owned about 0.12% of Acelyrin as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors have also recently added to or reduced their stakes in SLRN. ADAR1 Capital Management LLC increased its holdings in Acelyrin by 731.7% in the 4th quarter. ADAR1 Capital Management LLC now owns 444,967 shares of the company's stock valued at $1,397,000 after purchasing an additional 391,467 shares during the last quarter. Wellington Management Group LLP acquired a new position in shares of Acelyrin in the fourth quarter worth $567,000. ExodusPoint Capital Management LP acquired a new position in shares of Acelyrin in the fourth quarter worth $423,000. Barclays PLC grew its stake in shares of Acelyrin by 208.8% in the third quarter. Barclays PLC now owns 96,408 shares of the company's stock worth $475,000 after acquiring an additional 65,188 shares in the last quarter. Finally, Geode Capital Management LLC grew its stake in shares of Acelyrin by 3.5% in the fourth quarter. Geode Capital Management LLC now owns 1,709,086 shares of the company's stock worth $5,368,000 after acquiring an additional 57,472 shares in the last quarter. Institutional investors and hedge funds own 87.31% of the company's stock.

Insiders Place Their Bets

In other news, CEO Mina Kim sold 17,986 shares of Acelyrin stock in a transaction on Monday, March 17th. The shares were sold at an average price of $2.74, for a total transaction of $49,281.64. Following the completion of the sale, the chief executive officer now directly owns 671,753 shares of the company's stock, valued at approximately $1,840,603.22. The trade was a 2.61% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders own 13.60% of the company's stock.

Acelyrin Stock Performance

Shares of NASDAQ:SLRN remained flat at $2.27 during trading on Thursday. The business's fifty day simple moving average is $2.37 and its two-hundred day simple moving average is $2.90. The firm has a market capitalization of $229.17 million, a price-to-earnings ratio of -0.92 and a beta of 1.07. Acelyrin, Inc. has a twelve month low of $1.85 and a twelve month high of $7.25.

Acelyrin (NASDAQ:SLRN - Get Free Report) last posted its quarterly earnings results on Wednesday, May 14th. The company reported ($0.55) EPS for the quarter, topping the consensus estimate of ($0.95) by $0.40. As a group, equities analysts anticipate that Acelyrin, Inc. will post -2.53 earnings per share for the current fiscal year.

Acelyrin Company Profile

Acelyrin, Inc, a clinical biopharma company, focuses on identifying, acquiring, and accelerating the development and commercialization of transformative medicines. The company's lead product candidate is izokibep, a small protein therapeutic designed to inhibit IL-17A with high potency, which is in Phase 3 clinical trials for use in the treatment of Hidradenitis Suppurativa, Psoriatic Arthritis, and uveitis, as well as in Phase 2 clinical trials for use in the treatment of Axial Spondyloarthritis.